Overview of the drug development pipeline for malignant glioma
Gliomas comprise a group of tumors arising from the glial cells in the brain or spinal cord. They are broadly divided into astrocytomas and oligodendrogliomas. Astrocytomas are graded from I to IV. The most common subtype of primary brain tumors is malignant glioma, which is very aggressive, highly invasive, and neurologically destructive tumor. The symptoms of malignant glioma are headache, nausea or vomiting, confusion or a decline in brain function, memory loss, personality changes, and irritability. Technavio’s market research analysts have predicted that the increase in several instances of malignant glioma across the globe is expected to promote the drug development for malignant glioma.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of malignant glioma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development molecules for the treatment of malignant glioma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- AbbVie
- Advantagene
- BioMimetix
- DNAtrix
- Eli Lilly
- Orbus Therapeutics
Therapeutic assessment of the drug development pipeline for malignant glioma by route of administration
- Oral
- IV
- Intratuomoral
- IV and oral
- Parenteral and oral
- Subcutaneous
- IM and EP
- Intradermal injection
The oral route of administration (ROA) involves the application of the drug directly into the mouth, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for malignant glioma by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for malignant glioma are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for malignant glioma?
- What are the companies that are currently involved in the development of drug development molecules for malignant glioma?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX